These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 35579347)

  • 1. Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.
    Weber ANR; Tapia-Abellán A; Liu X; Dickhöfer S; Aróstegui JI; Pelegrín P; Welzel T; Kuemmerle-Deschner JB
    Rheumatology (Oxford); 2022 Oct; 61(10):e299-e313. PubMed ID: 35579347
    [No Abstract]   [Full Text] [Related]  

  • 2. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition.
    Vande Walle L; Stowe IB; Šácha P; Lee BL; Demon D; Fossoul A; Van Hauwermeiren F; Saavedra PHV; Šimon P; Šubrt V; Kostka L; Stivala CE; Pham VC; Staben ST; Yamazoe S; Konvalinka J; Kayagaki N; Lamkanfi M
    PLoS Biol; 2019 Sep; 17(9):e3000354. PubMed ID: 31525186
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3.
    Vande Walle L; Lamkanfi M
    Rheumatology (Oxford); 2023 May; 62(5):e166-e167. PubMed ID: 36562558
    [No Abstract]   [Full Text] [Related]  

  • 4. Comment on: Effective ex vivo inhibition of cryopyrin-associated periodic syndrome (CAPS)-associated mutant NLRP3 inflammasome by MCC950/CRID3: Reply.
    Weber ANR; Tapia-Abellán A; Liu X; Aróstegui JI; Pelegrín P; Welzel T; Kuemmerle-Deschner JB
    Rheumatology (Oxford); 2023 May; 62(5):e168-e169. PubMed ID: 36562561
    [No Abstract]   [Full Text] [Related]  

  • 5. A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases.
    Coll RC; Robertson AA; Chae JJ; Higgins SC; Muñoz-Planillo R; Inserra MC; Vetter I; Dungan LS; Monks BG; Stutz A; Croker DE; Butler MS; Haneklaus M; Sutton CE; Núñez G; Latz E; Kastner DL; Mills KH; Masters SL; Schroder K; Cooper MA; O'Neill LA
    Nat Med; 2015 Mar; 21(3):248-55. PubMed ID: 25686105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MCC950 in the treatment of NLRP3-mediated inflammatory diseases: Latest evidence and therapeutic outcomes.
    Bakhshi S; Shamsi S
    Int Immunopharmacol; 2022 May; 106():108595. PubMed ID: 35124417
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NLRP3 inflammasome and NLRP3-related autoinflammatory diseases: From cryopyrin function to targeted therapies.
    Moltrasio C; Romagnuolo M; Marzano AV
    Front Immunol; 2022; 13():1007705. PubMed ID: 36275641
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of NLRP3 inflammasome by MCC950 improves the metabolic outcome of islet transplantation by suppressing IL-1β and islet cellular death.
    Matsuoka T; Yoshimatsu G; Sakata N; Kawakami R; Tanaka T; Yamada T; Yoshida Y; Hasegawa S; Kodama S
    Sci Rep; 2020 Oct; 10(1):17920. PubMed ID: 33087823
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cryo-sensitive aggregation triggers NLRP3 inflammasome assembly in cryopyrin-associated periodic syndrome.
    Karasawa T; Komada T; Yamada N; Aizawa E; Mizushina Y; Watanabe S; Baatarjav C; Matsumura T; Takahashi M
    Elife; 2022 May; 11():. PubMed ID: 35616535
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Isoliquiritigenin inhibits NLRP3 inflammasome activation with CAPS mutations by suppressing caspase-1 activation and mutated NLRP3 aggregation.
    Usui-Kawanishi F; Kani K; Karasawa T; Honda H; Takayama N; Takahashi M; Takatsu K; Nagai Y
    Genes Cells; 2024 May; 29(5):423-431. PubMed ID: 38366709
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological Inhibition of the Nod-Like Receptor Family Pyrin Domain Containing 3 Inflammasome with MCC950.
    Corcoran SE; Halai R; Cooper MA
    Pharmacol Rev; 2021 Jul; 73(3):968-1000. PubMed ID: 34117094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic NLRP3 mutants form constitutively active inflammasomes resulting in immune-metabolic limitation of IL-1β production.
    Molina-López C; Hurtado-Navarro L; García CJ; Angosto-Bazarra D; Vallejo F; Tapia-Abellán A; Marques-Soares JR; Vargas C; Bujan-Rivas S; Tomás-Barberán FA; Arostegui JI; Pelegrin P
    Nat Commun; 2024 Feb; 15(1):1096. PubMed ID: 38321014
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of a Novel Missense Variant in NLRP3 Causing Atypical Cryopyrin-Associated Periodic Syndromes With Hearing Loss as the Primary Presentation, Responsive to Anti-Interleukin-1 Therapy.
    Birk-Bachar M; Cohen H; Sofrin-Drucker E; Kropach-Gilad N; Orenstein N; Lidzbarsky G; Kornreich L; Tal R; Amarilyo G; Levinsky Y; Sokolov M; Raveh E; Gerlic M; Harel L
    Arthritis Rheumatol; 2024 Mar; 76(3):444-454. PubMed ID: 37738164
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HSP90β controls NLRP3 autoactivation.
    Spel L; Hou C; Theodoropoulou K; Zaffalon L; Wang Z; Bertoni A; Volpi S; Hofer M; Gattorno M; Martinon F
    Sci Adv; 2024 Mar; 10(9):eadj6289. PubMed ID: 38416826
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low-frequency mosaicism in cryopyrin-associated periodic fever syndrome: mosaicism in systemic autoinflammatory diseases.
    Nishikomori R; Izawa K; Kambe N; Ohara O; Yasumi T
    Int Immunol; 2019 Sep; 31(10):649-655. PubMed ID: 31185077
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Divergence of IL-1, IL-18, and cell death in NLRP3 inflammasomopathies.
    Brydges SD; Broderick L; McGeough MD; Pena CA; Mueller JL; Hoffman HM
    J Clin Invest; 2013 Nov; 123(11):4695-705. PubMed ID: 24084736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MCC950 blocks enhanced interleukin-1β production in patients with NLRP3 low penetrance variants.
    Schuh E; Groß CJ; Wagner D; Schlüter M; Groß O; Kümpfel T
    Clin Immunol; 2019 Jun; 203():45-52. PubMed ID: 30974290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel knock-in mouse model of cryopyrin-associated periodic syndromes with development of amyloidosis: Therapeutic efficacy of proton pump inhibitors.
    Bertoni A; Carta S; Baldovini C; Penco F; Balza E; Borghini S; Di Duca M; Ognio E; Signori A; Nozza P; Schena F; Castellani P; Pastorino C; Perrone C; Obici L; Martini A; Ceccherini I; Gattorno M; Rubartelli A; Chiesa S
    J Allergy Clin Immunol; 2020 Jan; 145(1):368-378.e13. PubMed ID: 31194989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Novel Mutation in the Pyrin Domain of the NOD-like Receptor Family Pyrin Domain Containing Protein 3 in Muckle-Wells Syndrome.
    Hu J; Zhu Y; Zhang JZ; Zhang RG; Li HM
    Chin Med J (Engl); 2017 Mar; 130(5):586-593. PubMed ID: 28229991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cryopyrin-associated periodic syndrome (CAPS) in a patient with NLRP3 T348M mutation.
    Kreft B; Schlinsog AS; Wohlrab J
    J Dtsch Dermatol Ges; 2018 Oct; 16(10):1266-1268. PubMed ID: 30184330
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.